Dmitry I. Trukhan
Abstract
Currently, multimorbidity/comorbidity and drug safety are important components of rational pharmacotherapy in real clinical practice. Cardiovascular diseases occupy a leading place in the structure of non-infectious pathology of the adult population, being the main cause of early disability and premature death. In a review article, using clinical examples, the issues of rational pharmacotherapy in patients with cardiovascular diseases and concomitant comorbid/multimorbid pathology are considered.
Key words: real clinical practice, rational pharmacotherapy, multimorbidity, drug safety.
Key words: real clinical practice, rational pharmacotherapy, multimorbidity, drug safety.
About the Author
Dmitry I. Trukhan 11 Omsk State Medical University, Omsk, Russia
References
1. Rekomendatsii po ratsional'noi farmakoterapii bol'nykh serdechno-sosudistymi zabolevaniiami. VNOK. Sektsiia ratsional'noi farmakoterapii. Moscow, 2009 (in Russian).
2. Trukhan D.I., Tarasova L.V. Ratsional'naia farmakoterapiia i lekarstvennaia bezopasnost' v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6 (in Russian).
3. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. 2013; 11: 45–9 (in Russian).
4. Van den Akker M, Buntinx F, Metsemakers JF et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51 (5): 367–75. DOI: 10.1016/s0895-4356(97)00306-5
5. Lazebnik L.B., Efremov L.I., Konev Iu.V. Semanticheskie trudnosti pri polimorbidnosti. Klinicheskaia gerontologiia. 2015; 3–4: 44–6 (in Russian).
6. Chukaeva I.I., Samorodskaia I.V., Larina V.N. Sochetannaia patologiia: diskussionnye voprosy terminologii, ucheta i vliianiia na vybor taktiki vedeniia patsienta. Terapevticheskii arkhiv. 2018; 8: 125–30 (in Russian).
7. Lazebnik L.B., Konev Iu.V. Istoricheskie osobennosti i semanticheskie trudnosti ispol'zovaniia terminov, oboznachaiushchikh mnozhestvennost' zabolevanii u odnogo bol'nogo. Eksperimental'naia i klinicheskaia gastroenterologiia. 2018; 6 (154): 4–9 (in Russian).
8. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31 (in Russian).
9. Trukhan D.I. Nonsteroidal anti-inflammatory drugs through the prism comorbidity and drug safety:in focus amtolmetin guatsil. Consilium Medicum. 2015; 17 (2): 27–33 (in Russian).
10. Komorbidnost – problema XXI veka. Novye vozmozhnosti v arsenale vracha pri terapii komorbidnykh sostoianii. Consilium Medicum. 2015; 12: 13–9 (in Russian).
11. Trukhan D.I., Konshu N.V. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety. Handbook for Practitioners Doctors. 2019 2: 10–8 (in Russian).
12. Demograficheskii ezhegodnik Rossii. 2019. https://rosstat.gov.ru/ (in Russian).
13. Trukhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. Saint-Petersburg: SpetsLit, 2016 (in Russian).
14. Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. et al. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Rossiiskii kardiologicheskii zhurnal. 2006; 4: 45–50 (in Russian).
15. Shal'nova S., Kukushkin S., Manoshkina E., Timofeeva T. Arterial'naia gipertenziia i priverzhennost' terapii. Vrach. 2009; 12: 39–42 (in Russian).
16. Cannon CP, Rhee KE, Califf RM er al.; REACH Registry Investigators. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010; 105 (4): 445–52. DOI: 10.1016/j.amjcard.2009. 10.014
17. Klinicheskie rekomendatsii Khronicheskaia serdechnaia nedostatochnost' 2020. https://scardio.ru/content/Guidelines/2020/Clinic_ rekom_HSN.pdf (in Russian).
18. Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. Systemic Hypertension. 2020; 17 (1): 7–45. DOI: 10.26442/ 2075082X. 2020.1.200051 (in Russian).
19. Trukhan D.I., Filimonov S.N. Differentsial'nyi diagnoz osnovnykh sindromov i simptomov pri zabolevaniiakh pochek i mochevykh putei. Moscow: Prakticheskaia meditsina, 2019 (in Russian).
20. Twiss AM, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as main-tenance therapy for asthma. Br J Clin Pharmacol 2002; 53 (3): 243–9. DOI: 10.1046/j.0306-5251.2001.01560.x
21. Dart RA, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003; 123 (1): 222–43. DOI: 10.1378/chest.123.1.222
22. Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control 2013; 6: 101–9. DOI: 10.2147/ IBPC.S33982
23. Karoli N.A., Rebrov A.P. Sovremennye podkhody k lecheniiu arterial'noi gipertenzii u bol'nykh KhOBL (obzor literatury). Consilium Medicum. Respiratory Organs Diseases (Suppl.). 2013; 1: 53–9. (in Russian).
24. Herrin MA, Feemster LC, Crothers K et al. Combination antihypertensive therapy among patients with COPD. Chest 2013; 143 (5): 1312–20.
25. Trukhan D.I., Pozdniakov Iu.M. Vybor diuretika dlia lecheniia arterial'noi gipertenzii s pozitsii ratsional'noi farmakoterapii. Handbook for Practitioners Doctors. 2015; 10: 4–9 (in Russian).
26. Pereverzev A.Р., Ostroumova O.D. 2018 and 2019 Guidelines for the management of arterial hypertension: is there a place for unfixed drug combinations? Consilium Medicum. 2019; 21 (12): 118–127. DOI: 10.26442/20751753.2019.12.190747 (in Russian).
27. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–64. DOI: 10.1016/s0140-6736(97)05381-6
28. Forette F, Seux ML, Staessen JA et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162 (18): 2046–52. DOI: 10.1001/archinte.162.18.2046
29. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84. DOI: 10.1056/NEJM199903043400902
30. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20. DOI: 10.1001/archinte.160.2.211
31. Bufalino VJ, Masoudi FA, Stranne SK et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 2011; 123 (19): 2167–79. DOI: 10.1161/CIR.0b013e3182181529
32. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41. DOI: 10.1016/S0140-6736(01)06178-5
33. Forette F, Seux ML. Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe trial. Lancet 1998; 352: 1347–51. DOI: 10.1016/s0140-6736(98)03086-4
34. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226: 71–4. DOI: 10.1016/j.jns. 2004.09.015
35. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009; 118: 103–13. DOI: 10.1007/s00401-009-0522-3
36. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217–33. DOI: 10.1016/0006-8993(85)90680-8
37. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Ab across the blood-brain barrier. Mol Med 2011; 17 (3–4): 149–62. DOI: 10.2119/molmed.2010.00180
38. Bachmeier C, Beaulieu-Abdelahad D, Mullan M et al. Selective dihydropyiridine compounds facilitate the clearance of b-amyloid across the blood-brain barrier. Eur J Pharmacol 2011; 659 (2–3): 124–9. DOI: 10.1016/j.ejphar.2011.03.048
39. Kriuchkova O.N., Itskova E.A., Lutai Iu.A., Turna E.Iu. Novye gorizonty fiksirovannoi antigipertenzivnoi terapii. Krymskii terapevticheskii zhurnal. 2015; 2: 41–8 (in Russian).
40. Enanorm (Enanorm). http://www.rlsnet.ru/tn_index_id_ 49497.htm (in Russian).
41. Trukhan D.I., Pozdnyakov Yu.M. Actual aspects of rational pharmacotherapy in cardiology. Pros and cons fixed and arbitrary combinations of antihypertensive drugs. Consilium Medicum. 2016; 18 (1): 25–31 (in Russian).
42. Trukhan D.I., Pozdnyakov Yu.M. Vozmozhnosti nitrendipina v lechenii arterial'noi gipertenzii, profilaktike insul'ta i kognitivnykh narushenii v raznykh klinicheskikh situatsiiakh na ambulatorno-poliklinicheskom etape. Handbook for Practitioners Doctors. 2017; 3: 14–20 (in Russian).
43. Nitremed (Nitremed). https://www.rlsnet.ru/tn_index_id_ 87479.htm (in Russian).
44. Igase M, Kohara K, Miki T. The Association between Hypertension and Dementia in the Elderly. Int J Hypertens 2012; 2012: 320648. DOI: 10.1155/2012/320648
45. Chillon JM, Baumbach GL. Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats. Hypertension 2004; 43 (5): 1092–7. DOI: 10.1161/01.HYP.0000122874. 21730.81
46. Deev A.D., Martsevich S.Iu., Kutishenko N.P., Iakusevich V.V. Izuchenie effektivnosti i perenosimosti preparata INDAP v sravnenii s preparatami ARIFON i ARIFON retard u bol'nykh miagkoi i umerennoi arterial'noi gipertoniei, naznachaemykh kak v vide monoterapii, tak i v kombinatsii s ingibitorami APF. Mnogotsentrovoe, otkrytoe, randomizirovannoe perekrestnoe issledovanie. Rossiiskii kardiologicheskii zhurnal. 2006; 2: 78–82 (in Russian).
47. Deev A.D., Martsevich S.Iu., Bobkova L.P. et al. Terapiia arterial'noi gipertonii I i II stepeni. Otsenka terapevticheskoi ekvivalentnosti generika indapamida v sravnenii s obychnoi i retardirovannoi formoi original'nogo preparata. Handbook for Practitioners Doctors. 2006; 5: 33–7 (in Russian).
48. Kutishenko N.P., Iakusevich V.V., Deev A.D., Martsevich S.Iu. Otsenka terapevticheskoi ekvivalentnosti original'nogo indapamida i indapamida-dzhenerika u bol'nykh arterial'noi gipertoniei s pomoshch'iu randomizirovannogo perekrestnogo issledovaniia. Ratsional'naia farmakoterapiia v kardiologii. 2007; 2 (3): 26–30 (in Russian).
49. Mamedov M.N. Vozmozhnosti primeneniia indapamida na razlichnykh etapakh serdechno-sosudistogo kontinuuma i v otdel'nykh gruppakh patsientov. Rossiiskii kardiologicheskii zhurnal. 2010; 6: 107–11 (in Russian).
50. Trukhan D.I., Viktorova I.A. Diuretiki v lechenii arterial'noi gipertonii: vybor preparata s pozitsii ratsional'noi farmakoterapii i farmakoekonomicheskoi effektivnosti. Handbook for Practitioners Doctors. 2011; 8: 31–4 (in Russian).
51. Nedogoda S.V. Diuretiki pri arterial'noi gipertenzii: angely i demony. Rossiiskii kardiologicheskii zhurnal. 2013; 3: 62–6 (in Russian).
52. Pavlova T.V. Rol' diuretikov v lechenii AG. Handbook for Practitioners Doctors. 2013; 7: 37–41 (in Russian).
53. Trukhan D.I., Pozdniakov Iu.M. Vybor diuretika dlia lecheniia arterial'noi gipertenzii s pozitsii ratsional'noi farmakoterapii. Handbook for Practitioners Doctors. 2015; 10: 4–9 (in Russian).
54. Red'kin Iu.V., Nikolaev N.A. Farmakoekonomicheskaia effektivnost' razlichnykh skhem kombinirovannoi antigipertenzivnoi terapii u pozhilykh bol'nykh. Therapeutic Archive. 2005; 4: 62–6 (in Russian).
55. Statsenko M.E., Belenkova S.V., Shcherbakova T.G., Sporova O.E. Effektivnost' i bezopasnost' dlitel'noi terapii indapom u bol'nykh pozhilogo i starcheskogo vozrasta s arterial'noi gipertenziei. Rossiiskii kardiologicheskii zhurnal. 2009; 4: 49–54 (in Russian).
56. Trukhan D.I., Pavlova T.V., Viktorova I.A. Optimizatsiia nemedikamentoznogo i medikamentoznogo vozdeistviia na patogeneticheskie faktory razvitiia i techeniia arterial'noi gipertenzii v ramkakh novoi nauchno-issledovatel'skoi obrazovatel'noi ozdorovitel'noi programmy PERSPEKTIVA. Handbook for Practitioners Doctors. 2012; 11: 18–22 (in Russian).
57. Kochetkov A.I., Ostroumova O.D. The clinical implication of the target organ protective properties of antihypertensive drugs in new guidelines for the management of arterial hypertension: the benefit of calcium channel blockers and diuretics. Consilium Medicum. 2019; 21 (5): 11–8. DOI: 10.26442/20751753.2019.5.190417 (in Russian).
58. Lloyd-Sherlock P, Beard J, Nadia Minicuci N et al. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol 2014; 43 (1): 116–28. DOI: 10.1093/ije/dyt215
59. Klinicheskie rekomendatsii Arterial'naia gipertenziia u vzroslykh. RKO. 2020. https://scardio.ru/content/Guidelines/Clinic_rek_AG_ 2020.pdf (in Russian).
60. Pottegård A, Hallas J, Olesen M et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282 (4): 322–31. DOI: 10.1111/joim.12629
61. Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (4): 673–81.e9. DOI: 10.1016/j.jaad.2017.11.042
62. Rekomendatsii po lecheniiu stabil'noi ishemicheskoi bolezni serdtsa. ESC 2013. https://scardio.ru/content/Guidelines/IBS_rkj_7_14.pdf (in Russian).
63. Rekomendatsii ESC po diagnostike i lecheniiu khronicheskogo koronarnogo sindroma. Rossiiskii kardiologicheskii zhurnal. 2020; 25 (2): 3757. DOI: 10.15829/1560-4071-2020-2-3757 (in Russian).
64. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013; 16 (5): 821–47. DOI:10.18433/j3vw2f
65. Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Ratsional'noe ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. klinicheskie rekomendatsii. Nauchno-prakticheskaia revmatologiia. 2018; 56: 1–29. DOI: 10.14412/1995-4484-2018-1-29 (in Russian).
66. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123 (2): 114–21. DOI: 10.1111/bcpt.13023
67. Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Curr Opin Gastroenterol 2018; 34 (6): 451–7. DOI: 10.1097/ MOG.0000000000000471
68. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One 2019; 14 (5): e0216750. DOI: 10.1371/ journal.pone.0216750
69. Zirk-Sadowski J, Masoli JA, Delgado J et al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (7): 1332–8. DOI: 10.1111/jgs.15385
70. Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc 2018; 66 (12): 2428–9. DOI: 10.1111/jgs.15637
71. Grinevich V. B., Gubonina I. V., Doshchitsin V. L. et. al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020; 19 (4): 2630. DOI: 10.15829/1728-88002020-2630 (in Russian).
72. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019; 9 (1): 2282. DOI: 10.1038/s41598-019-39335-7
73. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastroin testinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc 2014; 89 (12): 1699–709. DOI: 10.1016/ j.mayocp.2014.07.015
74. Clooney AG, Bernstein CN, Leslie WD et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther 2016; 43 (9): 974–84. DOI: 10.1111/ apt.13568
75. Tai FWD, McAlindon ME.NSAIDs and the small bowel. Curr Opin Gastroenterol 2018; 34 (3): 175–82. DOI: 10.1097/MOG. 0000000000000427
76. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34 (11–12): 1269–81. DOI: 10.1111/j.13652036. 2011.04874.x
77. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107 (7): 1001–10. DOI: 10.1038/ ajg.2012.179
78. Karateev A.E., Moroz E.V., Kriukov E.V. Damage to the small intestine associated with non-steroidal anti-inflammatory drugs. Almanac of clinical medicine. 2019; 6: 559–67. DOI: 10.18786/2072-0505-201947-048 (in Russian).
79. Moroz E.V., Karateev A.E. Rebamipide: Effective drug prevention of NSAID enteropathy is possible. Sovremennaya Revmatologiya – Modern Rheumatology Journal. 2016; 10 (4): 97–105. DOI: 10.14412/1996-7012-2016-4-97-105 (in Russian).
80. Simanenkov V.I., Lutaenko E.A., Nikoghosyan A.A. Clinical and pharmacological features of the use of rebamipide in diseases of the gastrointestinal tract literature review. Meditsinskiy sovet – Medical Council. 2016; 19: 88–95. DOI: 10.21518 / 2079-701X-2016-19-88-95 (in Russian).
81. Gubska O.Ju., Kuzminets A.A. NSAID-Enterotoxicity: focus on the problem. Modern Gastroenterology. 2018; 5 (103): 50–9. DOI: http://doi.org/10.30978/MG-2018-5-50 (in Russian).
82. Chorbinskaya S.A., Kudryavceva N.A., Stepanova I.I. et al. NPVP inducirovannoe porazhenie zheludochno-kishechnogo trakta. Novye vozmozhnosti gastro- i enteroprotekcii. Kremlevskaya medicina. Klinicheskij vestnik. 2019; 4: 98–104. Available at: https://www.elibrary.ru/ item.asp?id=29953385 (in Russian).
83. Viktorova I.A., Trukhan D.I., Ivanova D.S. Modern opportunities for treatment and prevention of NSAID-induced enteropathies. Meditsinskiy sovet – Medical Council. 2020; (5): 30–40. DOI: 10.21518/2079-701X-2020-5-30-40 (in Russian).
84. Kurokawa S, Katsuki S, Fujita T et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol 2014; 49 (2): 239–44. DOI: 10.1007/s00535-013-0805-2
85. Watanabe T, Takeuchi T, Handa O et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirininduced moderate-to-severe small intestinal damage. PLoS One 2015; 10 (4): e0122330. DOI: 10.1371/journal. pone.0122330
86. Pittayanon R., Piyachaturawat P, Rerknimitr R et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol 2019; 34 (9): 1517–22. DOI: 10.1111/jgh.14671
87. Koretsune Y, Yamashita T, Yasaka M et al. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis. J Cardiol 2019; 73 (3): 204–209. DOI: 10.1016/j.jjcc.2018.09.004
88. Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Komorbidnaia patologiia v klinicheskoi praktike. Algoritmy diagnostiki i lecheniia. Kardiovaskuliarnaia terapiia i profilaktika. 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 (in Russian).
89. Korobeinikova E.R., Shkatova E.Yu. Application of rebamipide in the complex therapy of erosive lesions of the gastroduodenal zone in young patients. Medicinskij al'manah. 2018; 1 (52): 26–30. https://www.elibrary.ru/item.asp?id=32827407 (in Russian).
90. Dicheva D.T, Andreev D.N., Partsvania-Vinogradova I.V, Maev I.V Evaluation of efficacy and safety of rebamipide use in the triple therapy for Helicobacter pylori eradication: a pilot study Meditsinskiy sovet = Medical Council. 2018; 3: 86–9. DOI: 10.21518/2079-701X-2018-3-86-89 (in Russian).
91. Andreev D.N., Maev I.V., Dicheva D.T. et al. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Therapeutic Archive. 2018; 8: 27–32. DOI: 10.26442/terarkh 201890827-32 (in Russian).
92. Parfyonov A.I., Belostotsky N.I., Dbar S.R. et al. Enteropathy with Disorder of Membrane Digestion. Effektivnaya farmakoterapiya. 2018; 16; 20–7. https://www.elibrary.ru/item.asp?id=35192164 (in Russian).
93. Sagynbaeva V.E., Lazebnik L.B. Rebamipide is a modern gastrocytoprotector under erosive and ulcerative injuries of upper gastrointestinal tract: results of the research. Therapy. 2019; 8 (34): 173–83. DOI: 10.18565/therapy.2019.8.173–83 (in Russian).
94. Meshcheryakova G.M., Kopylova D.V., Vatutina V.S. Opyt primeneniya rebamipida v lechenii postluchevogo kolita Koloproktologiya. 2019; S3 (69): 87. https://www.elibrary.ru/item.asp?id=39222355 (in Russian).
For citation:Trukhan D.I. Rational pharmacotherapy in real clinical practice through the prism of multimorbidity and drug safety. Clinical review for general practice. 2020; 2: 29–39. DOI: 10.47407/kr2020.1.2.00015
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
